Frontlight ResearchEarly access
WithdrawnNo phase
HIV-1 and Brain Interaction on Smoking Comorbidity
Key facts
- Who runs it
- University of Maryland, Baltimore
- Where
- Baltimore, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Started
- 1 Dec 2019
- Ended
- 30 Oct 2025
- Type of study
- Interventional, 8 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Tobacco smoking and nicotine patch
- Record updated
- 10 March 2020
- Why it stopped
- We originally had a collaboration with a PI but he has left the University.
Who can take part
- Age
- 18 years to 60 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
Show the full registry criteria (14)Hide the full registry criteria
Who can take part
- Subjects between ages 18-60 in good health
- Ability to give written informed consent
- For people living with HIV: should be diagnosed with HIV two years or more and on ART two years or more
- For people living with HIV: should have achieved virologic suppression (defined as viral loads of ≤ 200 copies/ml), and without current signs of reactivation
Who cannot take part
- Significant alcohol or other drug use, other than nicotine dependence or marijuana use
- Unable to undergo MRI scanning due to metallic devices or objects (cardiac pacemaker or neurostimulator, some artificial joints, metal pins, surgical clips or other implanted metal parts) or claustrophobic to the scanner
- Any major medical illnesses to include, but not limited to, uncontrolled high blood pressure or high blood sugar, cardiovascular disease, asthma, peripheral vascular diseases, coagulopathies, history of superficial or deep vein thrombosis as per medical history
- Current substance-induced psychiatric disorders
- Gross structural abnormalities and/or have a history of syncope
- Any neurological illnesses to include, but not limited to, seizure disorders, multiple sclerosis, movement disorders, or history of head trauma, CVA, CNS tumor,
- For people living with HIV: having AIDS or non-AIDS-defining cancer or active CNS and other opportunistic disease
- For people living with HIV: on active treatment of hepatitis C virus (HCV)
- Inability to sign informed consent
- Positive urine pregnancy tests
Where in United States
- University of Maryland School of MedicineBaltimore, United States
About the trial
What the trial wants to find out
People living with HIV-1 have high rates of cigarette smoking, which may be related to nicotinic interaction with HIV-1 infection and brain function levels. The proposed project aims to understand these pathways using translational brain imaging and HIV-1 reactivation studies. The study proposes a targeted nicotine-brain investigation of the nicotinic effects in HIV-1 infection from cellular to brain circuitry levels.
The 8 groups in the trial
- HIV-1 smokersTreatment being tested
Treatment: Tobacco smoking and nicotine patch
- HIV-1 nonsmokersNo study treatment, for comparison
- Healthy control smokersExisting treatment, for comparison
Treatment: Tobacco smoking and nicotine patch
- Healthy control nonsmokersNo study treatment, for comparison
- HIV-1 nonsmokers using nicotine patchExisting treatment, for comparison
Treatment: Tobacco smoking and nicotine patch
- HIV-1 nonsmokers using placebo patchNo study treatment, for comparison
- Healthy control nonsmokers using nicotine patchExisting treatment, for comparison
Treatment: Tobacco smoking and nicotine patch
- Healthy control nonsmokers using placebo patchNo study treatment, for comparison
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 10 March 2020